DOCSLIB.ORG

Comprehensive Review on the Interaction Between Natural Compounds and Brain Receptors: Benefits and Toxicity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comprehensive Review on the Interaction Between Natural Compounds and Brain Receptors: Benefits and Toxicity European Journal of Medicinal Chemistry 174 (2019) 87e115 Contents lists available at ScienceDirect European Journal of Medicinal Chemistry journal homepage: http://www.elsevier.com/locate/ejmech Review article Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity * Ana R. Silva a, Clara Grosso b, , Cristina Delerue-Matos b,Joao~ M. Rocha a, c a Centre of Molecular and Environmental Biology (CBMA), Department of Biology (DB), University of Minho (UM), Campus Gualtar, P-4710-057, Braga, Portugal b REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Politecnico do Porto, Rua Dr. Antonio Bernardino de Almeida, 431, P-4249-015, Porto, Portugal c REQUIMTE/LAQV, Grupo de investigaçao~ de Química Organica^ Aplicada (QUINOA), Laboratorio de polifenois alimentares, Departamento de Química e Bioquímica (DQB), Faculdade de Ci^encias da Universidade do Porto (FCUP), Rua do Campo Alegre, s/n, P-4169-007, Porto, Portugal article info abstract Article history: Given their therapeutic activity, natural products have been used in traditional medicines throughout the Received 6 December 2018 centuries. The growing interest of the scientific community in phytopharmaceuticals, and more recently Received in revised form in marine products, has resulted in a significant number of research efforts towards understanding their 10 April 2019 effect in the treatment of neurodegenerative diseases, such as Alzheimer's (AD), Parkinson (PD) and Accepted 11 April 2019 Huntington (HD). Several studies have shown that many of the primary and secondary metabolites of Available online 17 April 2019 plants, marine organisms and others, have high affinities for various brain receptors and may play a crucial role in the treatment of diseases affecting the central nervous system (CNS) in mammalians. Keywords: Brain receptors Actually, such compounds may act on the brain receptors either by agonism, antagonism, allosteric Natural products modulation or other type of activity aimed at enhancing a certain effect. The current manuscript Neuroplasticity comprehensively reviews the state of the art on the interactions between natural compounds and brain Neuroinflammation receptors. This information is of foremost importance when it is intended to investigate and develop Oxidative stress cutting-edge drugs, more effective and with alternative mechanisms of action to the conventional drugs Blood-brain barrier presently used for the treatment of neurodegenerative diseases. Thus, we reviewed the effect of 173 natural products on neurotransmitter receptors, diabetes related receptors, neurotrophic factor related receptors, immune system related receptors, oxidative stress related receptors, transcription factors regulating gene expression related receptors and blood-brain barrier receptors. © 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC- ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Contents 1. Introduction . ................................................. 88 2. Neurotransmitter receptors . ................................................. 89 2.1. Acetylcholine receptors . ........................89 2.1.1. Nicotinic acetylcholine receptors (nAChRs) . ........................89 2.1.2. Muscarinic acetylcholine receptors (mAChRs) .............................................................................91 2.2. Glutamate receptors . ........................93 2.2.1. Ionotropic receptors . ........................93 2.2.2. Metabotropic glutamate receptors (mGluRs) ..............................................................................96 2.3. g-Aminobutyric acid receptors (GABARs) . ........................96 2.4. Cannabinoid receptors (CBRs) . .. ........................97 2.5. Dopamine receptors (DARs) . ........................98 3. Diabetes related receptors . ................................................ 100 3.1. Insulin and insulin-like growth factor (IGF) receptors (IR and IGFR) . .......................100 * Corresponding author. E-mail address: [email protected] (C. Grosso). https://doi.org/10.1016/j.ejmech.2019.04.028 0223-5234/© 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc- nd/4.0/). 88 A.R. Silva et al. / European Journal of Medicinal Chemistry 174 (2019) 87e115 3.2. Receptors for advanced glycation end-product (RAGE) . ...........................101 4. Neurotrophic factor (NTF) related receptors (NTFRs) . .................... 102 5. Immune system related receptors . .................... 103 6. Oxidative stress related receptors . .................... 104 7. Transcription factors regulating gene expression related receptors . .................... 106 8. Blood-brain barrier receptors . .................... 108 8.1. Apolipoprotein E (ApoE) or low-density lipoproteins (LDL) . ...........................108 9. Toxicity of natural compounds . .................... 108 10. Conclusions ............................................................... .................................. .................... 109 Conflicts of interest . .................... 109 Acknowledgements . ..................................................109 Supplementary data . .....................110 References . ..................................................110 1. Introduction concomitant deleterious effects on brain processes, such as learning þ and memory [15]. Excessive release of calcium ions (Ca2 ) e for Over the years, neurodegenerative diseases e such as Alz- instance, through glutamate receptors e contributes to mitochon- heimer's (AD), Parkinson's (PD) and Huntington's (HD) diseases e drial dysfunction, activation of proteases and mechanisms of have been the main focus of the research in neuroscience, so as to apoptosis, as well as to the accumulation of reactive oxygen species recognize the cellular changes and pathophysiological mechanisms (ROS) and to the release of nitric oxide ( NO) [16]. In turn, g-ami- involved [1]. This group of diseases is characterized by a gradual nobutyric (GABA) inhibition, mediated by the type A receptor motor and sensorial loss, as well as deficits of perceptual functions, (GABAAR), is a key element that provides the basis for synchronized knowledge and behaviour associated with neuronal death [2]. This neuronal activity [17]. In addition, the loss of dopaminergic neurons progressive loss of neurons is associated with deposition of pro- is a key mechanism for the neurodegeneration since they are teins in brain leading to changes in its physicochemical properties involved in functions such as voluntary movement, attention, [3]. memory and learning [18]. Furthermore, cannabinoid receptors are AD is related to amyloid-b (or Ab peptides), which is formed and also involved in the process, either by a decrease in the expression deposited in the brain due to the disturbance in the metabolism of of cannabinoid type 1 receptors (CB1Rs) e which is associated with the amyloid precursor protein (APP) e a glycoprotein that un- an increased release of glutamate, thus contributing to excitotox- dergoes proteolytic cleavage, through the a-orb-secretases, within icity mechanisms [19] e or by overexpression of cannabinoid type 2 the Ab domain. Firstly, Ab monomers aggregate into soluble olig- receptors (CB2Rs) e which are involved in processes of neuro- omers that then form insoluble oligomers, generating protofibrils inflammation [20,21]. In addition, the activation of receptors of and fibrils. Soluble Ab1-42 oligomers constitute the more toxic form advanced glycation end-products (RAGE) in neuronal cells pro- of the peptide [4]. Moreover, there are aggregates of hyper- motes synaptic dysfunction and, in microglia cells, induces phosphorylated tau-proteins (or t-proteins) that mediate neuro- inflammation [6,15]. At the genetic level, peroxisome proliferator- pathological processes associated with dementia [5,6] and there is activated receptors (PPARs) play a crucial role in downregulation also a decrease in the acetylcholine (ACh) levels [7]. In the case of of mitochondrial dysfunction, oxidative stress and neuro- PD, intraneuronal inclusions called Lewy bodies are present in the inflammation [22]. Such mechanisms of neuroinflammation substantia nigra. Lewy bodies are composed of abnormal a-synu- involve cells from the immune system (for example, microglia) clein which is nitrated, phosphorylated, abnormally conformed and which, in response to a persistent stimulus (for example, by protein aggregated, and presents altered solubility. Besides Lewy bodies, aggregates), activate the production of neurotoxic factors that abnormal neurites containing granular material and a-synuclein amplify the inflammatory states. At the same time, the scavenger filaments (Lewy neurites) are also found in the substantia nigra of receptors (SCARs) e highly expressed in astrocytes and microglia e PD patients [8]. PD is also characterized by the loss of dopaminergic are involved in the capture of several substrates, such as oxidized neurons [9]. Finally, in HD, the mutant Huntingtin protein alters proteins, lipids and apoptotic cells [23]. Receptors related to neu- neuronal function e being the striatum neurons more susceptible rotrophic factors (NTF) regulate the growth, differentiation and to its toxic effects, which explains the motor symptoms of this survival of the neurons from the central and peripheral nervous pathology [10].
Load more

Recommended publications
  • Structure￢ﾀﾓactivity Relationship Study at C9 Position of Kaitocephalin
    Bioorganic & Medicinal Chemistry Letters 26 (2016) 3543–3546 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl Structure–activity relationship study at C9 position of kaitocephalin Yoko Yasuno a, Makoto Hamada a, Yuya Yoshida a, Keiko Shimamoto b, Yasushi Shigeri c, ⇑ Toshifumi Akizawa d, Motomi Konishi d, Yasufumi Ohfune a, Tetsuro Shinada a, a Graduate School of Science, Osaka City University, 3-3-138, Sugimoto, Sumiyoshi, Osaka 558-8585, Japan b Bioorganic Research Institute, Suntory Foundation for Life Sciences, 8-1-1, Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0284, Japan c National Institute of Advanced Industrial Science and Technology, 1-8-31, Midorigaoka, Ikeda, Osaka 563-8577, Japan d Analytical Chemistry, Pharmaceutical Science, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan article info abstract Article history: Kaitocephalin (KCP) isolated from Eupenicillium shearii PF1191 is an unusual amino acid natural product Received 17 May 2016 in which serine, proline, and alanine moieties are liked with carbon–carbon bonds. KCP exhibits potent Revised 8 June 2016 and selective binding affinity for one of the ionotropic glutamate receptor subtypes, NMDA receptors Accepted 9 June 2016 (K = 7.8 nM). In this study, new structure–activity relationship studies at C9 of KCP were implemented. Available online 11 June 2016 i Eleven new KCP analogs with different substituents at C9 were prepared and employed for binding affin- ity tests using native ionotropic glutamate receptors. Replacement of the 3,5-dichloro-4-hydroxybenzoyl Keywords: group of KCP with a 3-phenylpropionyl group resulted in significant loss of binding affinity for NMDARs Ionotropic glutamate receptors (K = 1300 nM), indicating an indispensable role of the aromatic ring of KCP in the potent and selective Kaitocephalin i Natural product binding to NMDARs.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Implications of Dopamine D3 Receptor for Glaucoma: In-Silico and In-Vivo Studies
    International PhD Program in Neuropharmacology XXVI Cycle Implications of dopamine D3 receptor for glaucoma: in-silico and in-vivo studies PhD thesis Chiara Bianca Maria Platania Coordinator: Prof. Salvatore Salomone Tutor: Prof. Claudio Bucolo Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry. University of Catania - Medical School December 2013 Copyright ©: Chiara B. M. Platania - December 2013 2 TABLE OF CONTENTS ACKNOWLEDGEMENTS............................................................................ 4 LIST OF ABBREVIATIONS ........................................................................ 5 ABSTRACT ................................................................................................... 7 GLAUCOMA ................................................................................................ 9 Aqueous humor dynamics .................................................................. 10 Pharmacological treatments of glaucoma............................................ 12 Pharmacological perspectives in treatment of glaucoma ..................... 14 Animal models of glaucoma ............................................................... 18 G PROTEIN COUPLED RECEPTORS ....................................................... 21 GPCRs functions and structure ........................................................... 22 Molecular modeling of GPCRs ........................................................... 25 D2-like receptors ...............................................................................
    [Show full text]
  • Activation of D1R/PKA/Mtor Signaling Cascade in Medial
    www.nature.com/scientificreports OPEN Activation of D1R/PKA/mTOR signaling cascade in medial prefrontal cortex underlying the Received: 17 November 2016 Accepted: 3 May 2017 antidepressant effects ofl -SPD Published: xx xx xxxx Bing Zhang1,2,3, Fei Guo1, Yuqin Ma1,2, Yingcai Song3, Rong Lin3, Fu-Yi Shen3, Guo-Zhang Jin1, Yang Li 1 & Zhi-Qiang Liu3 Major depressive disorder (MDD) is a common neuropsychiatric disorder characterized by diverse symptoms. Although several antidepressants can influence dopamine system in the medial prefrontal cortex (mPFC), but the role of D1R or D2R subtypes of dopamine receptor during anti-depression process is still vague in PFC region. To address this question, we investigate the antidepressant effect of levo-stepholidine (l-SPD), an antipsychotic medication with unique pharmacological profile of D1R agonism and D2R antagonism, and clarified its molecular mechanisms in the mPFC. Our results showed that l-SPD exerted antidepressant-like effects on the Sprague-Dawley rat CMS model of depression. Mechanism studies revealed that l-SPD worked as a specific D1R agonist, rather than D2 antagonist, to activate downstream signaling of PKA/mTOR pathway, which resulted in increasing synaptogenesis-related proteins, such as PSD 95 and synapsin I. In addition, l-SPD triggered long- term synaptic potentiation (LTP) in the mPFC, which was blocked by the inhibition of D1R, PKA, and mTOR, supporting that selective activation of D1R enhanced excitatory synaptic transduction in PFC. Our findings suggest a critical role of D1R/PKA/mTOR signaling cascade in the mPFC during thel -SPD mediated antidepressant process, which may also provide new insights into the role of mesocortical dopaminergic system in antidepressant effects.
    [Show full text]
  • Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems ELENI BAGLI 1,2 , ANNA GOUSSIA 3, MARILITA M
    in vivo 30 : 535-548 (2016) Review Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems ELENI BAGLI 1,2 , ANNA GOUSSIA 3, MARILITA M. MOSCHOS 4, NIKI AGNANTIS 3 and GEORGIOS KITSOS 2 1Institute of Molecular Biology and Biotechnology - FORTH, Division of Biomedical Research, Ioannina, Greece; 2Department of Ophthalmology, University of Ioannina, Ioannina, Greece; 3Department of Pathology, University of Ioannina, Ioannina, Greece; 4Department of Ophthalmology, University of Athens, Athens, Greece Abstract. Neurodegeneration characterizes pathologic pathological events, including oxidative stress, mitochondrial conditions, ranging from Alzheimer’s disease to glaucoma, dysfunction, inflammation and protein aggregation (2, 3). with devastating social and economic effects. It is a The increasing knowledge of the cellular and molecular complex process implicating a series of molecular and events underlying the degenerative process has greatly cellular events, such as oxidative stress, mitochondrial stimulated research for identifying compounds capable of dysfunction, protein misfolding, excitotoxicity and stopping or, at least, slowing the progress of neural inflammation. Natural compounds, because of their broad deterioration. spectrum of pharmacological and biological activities, Natural compounds are complex chemical multiple-target could be possible candidates for the management of such molecules found mainly in plants and microorganisms (4). multifactorial morbidities. However, their therapeutic These agents
    [Show full text]
  • Handbook of Schizophrenia Spectrum Disorders, Volume III
    Handbook of Schizophrenia Spectrum Disorders, Volume III Michael S. Ritsner Editor Handbook of Schizophrenia Spectrum Disorders, Volume III Therapeutic Approaches, Comorbidity, and Outcomes 123 Editor Michael S. Ritsner Technion – Israel Institute of Technology Rappaport Faculty of Medicine Haifa Israel [email protected] ISBN 978-94-007-0833-4 e-ISBN 978-94-007-0834-1 DOI 10.1007/978-94-007-0834-1 Springer Dordrecht Heidelberg London New York Library of Congress Control Number: 2011924745 © Springer Science+Business Media B.V. 2011 No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Foreword Schizophrenia Spectrum Disorders: Insights from Views Across 100 years Schizophrenia spectrum and related disorders such as schizoaffective and mood dis- orders, schizophreniform disorders, brief psychotic disorders, delusional and shared psychotic disorders, and personality (i.e., schizotypal, paranoid, and schizoid per- sonality) disorders are the most debilitating forms of mental illness, worldwide. There are 89,377 citations (including 10,760 reviews) related to “schizophrenia” and 2118 (including 296 reviews) related to “schizophrenia spectrum” in PubMed (accessed on August 12, 2010). The classification of these disorders, in particular, of schizophrenia, schizoaf- fective and mood disorders (referred to as functional psychoses), has been debated for decades, and its validity remains controversial.
    [Show full text]
  • Guidelines for Biological Treatment of Schizophrenia, Part 2
    The World Journal of Biological Psychiatry, 2013; 14: 2–44 GUIDELINES World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects ALKOMIET HASAN 1 , PETER FALKAI1 , THOMAS WOBROCK 2 , JEFFREY LIEBERMAN 3 , BIRTE GLENTHOJ 4 , WAGNER F. GATTAZ 5 , FLORENCE THIBAUT6 & HANS-JÜ RGEN M Ö LLER 1 , WFSBP Task force on Treatment Guidelines for Schizophrenia * 1 Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany, 2 Centre of Mental Health, Darmstadt-Dieburg Clinics, Darmstadt, Germany, 3 Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, Lieber Center for Schizophrenia Research, New York, USA, 4 Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital, Psychiatric Center Glostrup, Denmark, 5 Department of Psychiatry, University of Sao Paulo, Brazil, and 6 University Hospital Ch. Nicolle, Faculty of Medicine, INSERM, Rouen, France Abstract These updated guidelines are based on a fi rst edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence- based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifi cally meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the fi rst version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update.
    [Show full text]
  • Vol 32 No. 3.Cdr
    Chemistry in Sri Lanka ISSN 1012 - 8999 The Tri-Annual Publication of the Institute of Chemistry Ceylon Founded in 1971, Incorporated by Act of Parliament No. 15 of 1972 Successor to the Chemical Society of Ceylon, founded on 25th January 1941 Vol. 32 No. 3 September 2015 Pages Council 2015/2016 02 Outline of our Institute 02 Chemistry in Sri Lanka 02 Committees 2015/2016 03 Message from the President 04 Cover Page 04 Guest Editorial: Role of Professional Chemists for National Development 05 Presidential Address: Chemical Sciences in Food Safety and Food Security 06 Call for Nominations for Institute of Chemistry Gold Medal 2016 08 Forty Fourth Annual Sessions and Seventy Fourth Anniversary Celebrations 2015 Chief Guest’s Address: Chemical Sciences in Food Safety and Security 09 Guest of Honour’s Address: Chemists and Professionalism 11 Theme Seminar on “The Role of Chemistry in Food Safety and Food Security” Chief Guest’s Address: Food Safety 12 Food Security and Water Quality 14 Dr. C L De Silva Gold Medal Award 2015 Exploring Endolichenic Fungi in Sri Lanka as a Potential Treasure Trove for Bioactive Small Molecules; A Journey through the Fascinating World of endolichenic fungi 19 Chandrasena Memorial Award 2015 Lichens as a Treasure Chest of Bioactive Metabolites 30 Kandiah Memorial Graduateship Award 2015 Time Course Variation of Nutraceuticals and Antioxidant Activity during Steeping of CTC Black Tea (Camellia sinensis L.) Manufactured in Sri Lanka 34 Guest Articles The Asymmetric [C+NC+CC] Coupling Reaction: Development and Application
    [Show full text]
  • Organic & Biomolecular Chemistry
    Organic & Biomolecular Chemistry Accepted Manuscript This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/obc Page 1 of 5 OrganicPlease & Biomoleculardo not adjust margins Chemistry Journal Name COMMUNICATION (7 S)-Kaitocephalin as a potent NMDA receptor selective ligand Yoko Yasuno a, Makoto Hamada a, Masanori Kawasaki a, Keiko Shimamoto b, Yasushi, Shigeri c, Received 00th January 20xx, Toshifumi Akizawa d, Motomi Konishi d, Yasufumi, Ohfune a, Tetsuro Shinada a* Accepted 00th January 20xx Manuscript DOI: 10.1039/x0xx00000x www.rsc.org/ Structure-activity relationship (SAR) study of kaitocephalin known from the glutamate overstimulation using NMDA antagonists to be a potent naturally occuring NMDA receptor ligand was has become a promising strategy for drug discovery of these performed.
    [Show full text]
  • Serotonergic System Modulation Holds Promise for L‐Dopa‐Induced Dyskinesias in Hemiparkinsonian Rats: a Systematic Review
    EXCLI Journal 2020;19:268-295 – ISSN 1611-2156 Received: January 03, 2020, accepted: February 24, 2020, published: March 02, 2020 Review article: SEROTONERGIC SYSTEM MODULATION HOLDS PROMISE FOR L‐DOPA‐INDUCED DYSKINESIAS IN HEMIPARKINSONIAN RATS: A SYSTEMATIC REVIEW Fereshteh Farajdokht1, 2, Saeed Sadigh-Eteghad2, Alireza Majdi2, Fariba Pashazadeh1,3, Seyyed Mehdi Vatandoust2, Mojtaba Ziaee4,5, Fatemeh Safari6, Pouran Karimi2, Javad Mahmoudi2* 1 Research Center for Evidence-Based Medicine (EBM), Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran 2 Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran 3 Iranian Evidence-Based Medicine (EBM) Center, a Joanna Briggs Institute Affiliated Group 4 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 5 Phytopharmacology Research Center, Maragheh University of Medical Sciences, Maragheh, Iran 6 Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran * Corresponding author: Dr. Javad Mahmoudi, Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran, Postal code: 5166614756, Iran, Tel: +984133351284, E-mails: [email protected], [email protected] http://dx.doi.org/10.17179/excli2020-1024 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). ABSTRACT The alleged effects of serotonergic agents in alleviating levodopa-induced dyskinesias (LIDs) in parkinsonian patients are debatable. To this end, we systematically reviewed the serotonergic agents used for the treatment of LIDs in a 6-hydroxydopamine model of Parkinson’s disease in rats. We searched MEDLINE via PubMed, Embase, Google Scholar, and Proquest for entries no later than March 2018, and restricted the search to publications on serotonergic agents used for the treatment of LIDs in hemiparkinsonian rats.
    [Show full text]
  • A 1A9, A431 and A549 Cell Lines, 3478 12Α,13Α-Aziridinyl Epothilone
    Index A Acanthoscelides obtectus, 4091 1A9, A431 and A549 cell lines, 3478 Acanthostrongylophora, 1293 12a,13a-Aziridinyl epothilone derivatives, 990 Acari, 4070, 4083 Aaptos ciliata, 1292 Acaricides, 4070, 4076, 4083 AATs. See Anthocyanin acyltransferases Accelerated solvent extraction (ASE), 1017, (AATs) 2017, 2021–2023, 2032, 2037, 2111 Ab (1-42), 2287 p-Acceptors, 692 ABA biosynthesis, 1736 Accretion, 2405 Ab aggregation, 2286 Accumulation, 2321 Abdominal troubles, 3477 Acetaldehyde (ATL), 2902 Aberrant behavior, 1375 Acetaldehyde acid, 1783 Aberrant estrous cycles, 2421 Acetate, 50, 59 Abies alba, 2980 Acetate-mevalonate (Ac-MEV), 2943 Abietadiene synthase, 2725 Acetate pathway, 2314 Abiotic and biotic elicitors, 2783 Acetic acid (ACE), 851, 1608, 2884 Abiotic factor, 1697 Acetogenic bacteria, 2443 Abiotic stresses, 2930 Acetone, 3371 Ab neuropathology, 2285 Acetonitrile, 691, 1170, 1175 Ab oligomerization, 2285 3-Acetylaconitine, 1508 Ab oligomers, 2283 Acetyl-ACP, 963 Ab peptides, 1308, 2285 Acetyl-and butyrylcholinesterase inhibitors, Ab polymerization, 2287 3488 Abrin, 296 Acetylcholine (ACh), 1241, 1306, 1333, 1526, Abscisic acid (ABA), 2860, 3591 1527, 1529, 1530, 3710 Absolute configuration, 930, 3320 Acetylcholine esterase, 51, 52 Absolute configuration of monosaccharides, Acetylcholine esterase inhibitor activity, 2906 3319 Acetylcholinesterase (AChE), 41, 1246, 1308, Absorbance (A), 3334, 3380 1334, 1527, 1529–1533, 1535, 4097 Absorbance spectrum, 3929, 3933, 3934 Acetyl-CoA, 61, 584 Absorption, 1230, 2321, 2470–2476, Acetyl-CoA carboxylase (ACC), 1658, 1825 2478–2481, 3134, 3377, 3616, 4024 3-Acetyldeoxynivalenol, 3127, 3145 coefficient, 3380 15-Acetyl deoxynivalenol (15ADON), and metabolism, 1428 3127, 3145 wavelength, 4028 Acetylerucifoline, 1061 Abusive correlations, 2410 Acetylgaertneroside, 3054 Acacetin, 1830 60-O-Acetylgeniposide, 3058 Acacia, 865 8-O-Acetylharpagide, 3055 a2C adrenergic, 4124 Acetylintermedine, 1061 Acanthaceae, 801 Acetyllycopsamine, 1061 K.G.
    [Show full text]